Ann Lab Med.
2023 May;43(3):290-294. 10.3343/alm.2023.43.3.290.
Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations
- Affiliations
-
- 1Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea
- 2Department of Laboratory Medicine, Korea University Anam Hospital, Seoul, Korea
- 3Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea
- KMID: 2551713
- DOI: http://doi.org/10.3343/alm.2023.43.3.290
Abstract
- While numerous studies have evaluated humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, data on the cellular responses to these vaccines remain sparse. We evaluated T cell responses to ChAdOx1-nCoV-19 and BNT162b2 vaccinations using an interferon gamma (IFN-γ) release assay (IGRA). ChAdOx1-nCoV-19- and BNT162b2-vaccinated participants initially showed stronger T cell responses than unvaccinated controls. The T cell response decreased over time and increased substantially after the administration of a BNT162b2 booster dose. Changes in the T cell response were less significant than those in the anti-receptor-binding domain IgG antibody titer. The study results can serve as baseline data for T cell responses after SARS-CoV-2 vaccination and suggest that the IGRA can be useful in monitoring immunogenicity.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines
- Evaluation of Reactogenicity and Neutralizing Antibody Responses 6 Months Post-Vaccination with Monovalent COVID-19 Vaccine
- Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
- Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19
- Two Case Reports of Leukocytoclastic Vasculitis after ChAdOx1 nCoV-19 Vaccine
